Huntington’s disease: Pathophysiology and therapeutic intervention
Division of Neuroscience, Department of Pharmacology, Smt. Kishoritai Bhoyar College of Pharmacy, New Kamptee, Nagpur 441 002 (M.S.), India.
Review Article
GSC Biological and Pharmaceutical Sciences, 2021, 15(02), 171–184.
Article DOI: 10.30574/gscbps.2021.15.2.0140
Publication history:
Received on 21 April 2021; revised on 22 May 2021; accepted on 25 May 2021
Abstract:
Huntington's disease [HD] is a progressive neurodegenerative condition characterized by movement disorder, cognitive impairment, and behavioral symptoms. It is inherited as an autosomal-dominant trait and normally manifests in mid-adulthood. HD is common in India and parts of Central Asia, with a prevalence rate of 4–8 per 100 000 in most European populations. Juvenile onset affects around 5–10% of cases, with signs appearing before the age of 20. Patients may show more parkinsonian symptoms such as bradykinesia, dystonia, tremors and a cognitive deficit in place of chorea. There is no therapy that can completely stop the condition from progressing. There are medications that can help to regulate chorea, dystonia, mental, and psychiatric disturbances. The study covers the disease's pathophysiology, as well as plants and phytochemicals that have been shown to be beneficial.
Keywords:
Huntington's disease; Neurotransmission; Etiology; Pathophysiology; Treatment
Full text article in PDF:
Copyright information:
Copyright © 2021 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0
